A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under trial conditions, although there is limited data on long-term usage.
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under ...